New Mexico 2025 Regular Session

New Mexico Senate Bill SB219

Introduced
1/30/25  
Report Pass
2/12/25  
Report Pass
3/6/25  
Report Pass
3/10/25  
Engrossed
3/12/25  
Report Pass
3/17/25  
Enrolled
3/18/25  
Chaptered
4/7/25  

Caption

Medical Psilocybin Act

Impact

If enacted, the Medical Psilocybin Act will amend existing laws, notably the Controlled Substances Act, by removing psilocybin and psilocin from schedule I classifications for the purposes of medical treatment. The law will also provide protections for producers and clinicians involved in the psilocybin administration process against criminal and civil penalties as long as they comply with the guidelines set forth in the Act. The establishment of a medical psilocybin treatment equity fund will help ensure access for qualifying patients who meet predetermined income criteria, facilitating broader public health benefits and research opportunities.

Summary

Senate Bill 219, known as the Medical Psilocybin Act, aims to establish a legal framework for the medical use of psilocybin, a psychedelic compound found in certain mushrooms, to treat qualified medical conditions. The bill allows for the use of psilocybin in approved clinical settings under the supervision of licensed healthcare providers. It seeks to create a system for the production, administration, and oversight of psilocybin treatments, including the establishment of an advisory board to recommend eligible medical conditions and best practices for use. Conditions eligible for treatment may include major treatment-resistant depression, posttraumatic stress disorder (PTSD), substance use disorders, and other applicable conditions as determined by the department of health.

Contention

The legislative discussions surrounding SB 219 highlighted both support and opposition. Proponents argue that the therapeutic potential of psilocybin can significantly address issues of mental health, particularly in populations suffering from treatment-resistant conditions. Critics, however, express concerns regarding the safety and efficacy of psilocybin as a treatment option, underscoring the need for thorough research and data collection. The establishment of an advisory board is intended to address these concerns by providing a platform for continuous evaluation and adaptation of the treatment protocols and practices as necessary.

Companion Bills

No companion bills found.

Similar Bills

MN HF2699

Psilocybin cultivation, possession, transportation, and personal use by individuals 21 years of age or older authorized; protections established; public education and harm reduction programs established; Psychedelic Medicine Board established; criminal penalties provided; rulemaking authorized; civil actions authorized; and money appropriated.

NJ A3852

"Psilocybin Behavioral Health Access and Services Act"; authorizes production and use of psilocybin to promote health and wellness.

NJ S2283

"Psilocybin Behavioral Health Access and Services Act"; authorizes production and use of psilocybin to promote health and wellness.

IA HF978

A bill for an act relating to the production of psilocybin and the administration of psilocybin to persons with post-traumatic stress disorder, and providing penalties.(Formerly HF 620.)

IA HF620

A bill for an act relating to the production of psilocybin and the administration of psilocybin to persons with post-traumatic stress disorder, and providing penalties.(See HF 978.)

IL SB2184

USE AND RESEARCH-ENTHEOGENS

MA H2506

Decriminalizing psilocybin as a treatment for PTSD and certain other conditions

NM SB410

Crystalline Polymorph Psilocybin Rescheduling